Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
41. |
ECCT/23/03/03 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/USAMRD (Kericho county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) |
12-05-2023 |
View |
42. |
ECCT/22/11/03 | BFAST A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya Aga Khan University, Nairobi |
12-04-2023 |
View |
43. |
ECCT/22/12/03 | heredERA A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO + TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER |
Principal Investigator(s) 1. Mansoor Saleh 2. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
12-04-2023 |
View |
44. |
ECCT/22/11/02 | UNCPM 22120 5-FU Study UNCPM 22120: Safety of adjuvant, self-administered intravaginal 5-fluorouracil (5-FU) cream following cervical intraepithelial neoplasia grade 2 and 3 (CIN2/3) treatment among HIV-positive women in Kenya: A pilot study |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Chemtai Mungo Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) |
01-03-2023 |
View |
45. |
ECCT/22/10/05 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Videlis N Nduba Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) |
26-02-2023 |
View |
46. |
ECCT/22/10/02 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Janet N Oyieko Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Strathmore University Medical Centre (Nairobi City county) |
10-02-2023 |
View |
47. |
ECCT/22/09/01 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Godfrey Allan Otieno Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Kombewa Clinical Research Centre (Kisumu county) |
20-12-2022 |
View |
48. |
ECCT/22/08/02 | AIM-LVRNA009-II_III-01 A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde |
Principal Investigator(s) 1. Bernhards Ogutu 2. Lucas Otieno 3. Videlis Nduba 4. Bernhards Ogutu 5. Jacqueline Mirera 6. Jacqueline Mirera Site(s) in Kenya 1. Siaya Clinical Trials Unit (Siaya county) 2. Homa Bay Clinical Trials Unit (Homa Bay county) 3. Ahero Clinical Trials Unit (Kisumu county) 4. CREA-N Machakos (Machakos county) 5. CREA-N Nakuru (Nakuru county) 6. Victoria Biomedical Research Institue (Kisumu county) |
22-11-2022 |
View |
49. |
ECCT/22/02/02 | The Women TAF-FTC Benchmark Safety and Pharmacokinetics of TAF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women |
Principal Investigator(s) 1. Dr. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
18-11-2022 |
View |
50. |
ECCT/22/07/01 | GBT021601-021 Study A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Berhnards Ragama Ogutu 3. Videlis Nduba 4. Berhnards Ragama Ogutu Site(s) in Kenya 1. Gertude\'s Children\'s Hospital (Nairobi City county) 2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county) 3. / KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county) 4. KENYA MEDICAL RESEARCH INSTITUTE- SIAYA COUNTY REFERAL HOSPITAL (Siaya county) |
17-10-2022 |
View |